Tanvir Zaman Shoyshob

Mr. Tanvir Zaman Shoyshob

Biochemistry and Molecular Biology, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh
+1
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in Immuno
Verified
Journal Article
Open access
PDF file
Tanvir Zaman ShoyshobTanvir Zaman Shoyshob
Tanvir Zaman Shoyshob
Irin Amin HeyaIrin Amin Heya
Irin Amin Heya
NANusrat Afrin
Nusrat Afrin
MEMansura Akter Enni
Mansura Akter Enni
AJAsha Israt Jahan
Asha Israt Jahan
Md Jamal UddinMd Jamal Uddin
Md Jamal Uddin
Dengue fever is currently a major global issue, especially in tropical and subtropical countries. The absence of specific antiviral medications supports alternative dengue treatment strategies. South Asian countries have been using Carica papaya leaves as a traditional remedy for dengue for many years. Carica papaya possesses several biological features, including anti-inflammatory, antiviral, cancer-fighting, anti-diabetic, and antioxidant qualities. Additionally, numerous studies have demonstrated that bioactive compounds found in papaya leaf extracts, including carpaine, dehydrocarpaine I and II, chymopapain, and papain, significantly influence platelet counts, while phenolic compounds, such as chlorogenic acid, kaemferol, protocatechuic acid, quercetin, and 5,7-dimethoxycoumarin significantly inhibit viral replication in dengue patients, with negligible side effects. Carica papaya may be considered a viable pharmacological candidate with several targets for treating dengue. It has been shown to prevent infections, reduce oxidative stress, control cytokine storms and the immune system, lessen thrombocytopenia, and increase the body’s protein and hemoglobin levels. This literature review highlights the pathophysiological mechanism of dengue, as well as the pharmacological action of Carica papaya, both of which combat this debilitating disease. Despite these findings, additional investigation, including clinical studies, is necessary to confirm the effectiveness and safety of papaya-based treatments. It is necessary to address issues like standardizing papaya extracts, figuring out the best dosages, and assessing any drug interactions.

1 January 2025 in Advances in Pharmacological and Pharmaceutical Sciences
Verified
Journal Article
Open access
Partha BiswasPartha Biswas
Partha Biswas
MD. Hasanur RahmanMD. Hasanur Rahman
MD. Hasanur Rahman
ATAfrida Tabassum
Afrida Tabassum
Tanvir Zaman ShoyshobTanvir Zaman Shoyshob
Tanvir Zaman Shoyshob
MJMaroua Jalouli
Maroua Jalouli
Md Ataur RahmanMd Ataur Rahman
Md Ataur Rahman
Neurodegenerative diseases (NDs) represent an increasingly important burden of disease, particularly in the aging population. The etiology of NDs like Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD) is associated with progressive neuronal degeneration and a paucity of effective therapies. Accumulating evidence suggests that common and intersecting genetic and pathological pathways play a critical role in disease onset and progression, revealing new opportunities for target discovery. Here, we review promising therapeutic targets based on the convergence of genetics, molecular pathology, and cellular signaling in neurodegeneration. This narrative will focus on key proteins (amyloid‐beta [Aβ], tau, and α‐synuclein) and enzymes (acetylcholinesterase and asparagine endopeptidase [AEP]), including their pathological significance and therapeutic implications. N‐Methyl‐D‐aspartate receptors (NMDARs) and cholinergic receptor subtypes are highlighted as important regulators of neurotoxicity, synaptic transmission, and inflammation. Emerging advances in genomics, neuroimaging, and drug delivery are poised to advance precision medicine strategies for early diagnosis and intervention. Important challenges remain, including the complexity of the blood–brain barrier (BBB), pathology heterogeneity, and the need for new biomarkers. We propose that a shift from phenotype‐driven diagnoses to mechanistic, genetically informed approaches may improve treatment efficacy. Target identification, validation, and targeted delivery are critical considerations for the success of future therapeutic development. This integrated view will help to inform and improve drug discovery and personalized medicine approaches in the field of neurodegeneration.

1 January 2025 in Journal of Advanced Biotechnology and Experimental Therapeutics
Verified
Journal Article
Closed access
Tanvir Zaman ShoyshobTanvir Zaman Shoyshob
Tanvir Zaman Shoyshob
SASumaya Akter
Sumaya Akter
MUMuhammad Uddin
Muhammad Uddin
MFMithila Farjana
Mithila Farjana
AMAkhi Moni
Akhi Moni
UDUddin
Uddin
Currently, liver diseases have become a serious global health issue, and this situation occurs due to the exposure of the liver to different agents, such as chemicals, alcohol, viruses, and autoimmune diseases. Mangiferin is a natural bioactive xanthone C-glycoside compound and a potent antioxidant that is widely found in medicinal plants such as the leaves of Mangifera indica L. (Anacardiaceae). It possesses a wide range of biological properties, such as antidiabetic, hepatoprotective, anti-inflammatory, antioxidant, and anticarcinogenic activities. The purpose of this literature review was to delineate the hepatoprotective effects of mangiferin, a natural bioactive compound without side effects, and explain how it protects the liver via the suppression of pathological conditions involved in liver diseases. Relevant published research articles from peer-reviewed journals were searched in PubMed and Google Scholar to gain insights into the consequences of mangiferin in liver diseases. Several studies have suggested that pretreatment with mangiferin decreases hepatic inflammation, oxidative stress, apoptosis, fibrosis, endoplasmic reticulum (ER) stress, and hepatic dysfunction and concomitantly ameliorates the morphological structures of the liver. Therefore, mangiferin could be considered a multitarget therapeutic and promising drug candidate for the treatment of hepatic diseases, although a detailed mechanistic explanation needs to be provided. This literature review highlights the pathological conditions (inflammation, oxidative stress, apoptosis, ER stress) associated with liver diseases as well as the hepatoprotective and therapeutic effects of mangiferin in the liver.

1 January 2026 in Journal of Food Biochemistry
Verified
Journal Article
Open access
AKArman Mahmud Khan
Arman Mahmud Khan
MMMasudur Rahman Munna
Masudur Rahman Munna
Tanvir Zaman ShoyshobTanvir Zaman Shoyshob
Tanvir Zaman Shoyshob
RHRezwanul Haque
Rezwanul Haque
Md Abdul HannanMd Abdul Hannan
Md Abdul Hannan
Bioactive peptides (BAPs) derived from dietary proteins are increasingly recognized for their functional and therapeutic properties, making them promising candidates for functional foods and nutraceuticals. In this study, phycobiliproteins (PBPs), the major pigment proteins responsible for the vibrant coloration in the red alga Gracilaria tenuistipitata , were enzymatically hydrolyzed to generate BAPs. The antioxidant and anti‐inflammatory potential of the resulting BAPs was further investigated. PBPs were extracted from G. tenuistipitata using phosphate buffer solution (PBS) with repeated freeze–thaw cycles, followed by partial purification through isoelectric precipitation at pH 4. The PBPs were then subjected to in vitro enzymatic hydrolysis with various digestive enzymes, including α‐chymotrypsin, trypsin, pepsin, and their combinations, to produce BAPs. In vitro antioxidant (DPPH and ABTS scavenging) and anti‐inflammatory (trypsin and hemolysis inhibition) assays were conducted to determine the bioactivities of the resulting hydrolysates. Isoelectric precipitation yielded 1.75 and 1.72 mg/g dry weight (DW) of phycoerythrin (PE) and phycocyanin (PC), respectively, with purity indices improving significantly (PE: 0.7, PC: 0.61, PBP: 1.31) compared to crude PBPs (PE: 0.63, PC: 0.5, PBP: 1.13). The combined hydrolysate exhibited the highest antioxidant activity (DPPH and ABTS scavenging capacities of 44.77 ± 1.12 and 71.10 ± 0.77 μmol TE/g DW, respectively), compared with undigested PBPs. Additionally, the hydrolysates displayed strong anti‐inflammatory effects, with the combined hydrolysate showing higher trypsin inhibition (41.35 ± 0.69 mg QE/g DW) than undigested PBPs (27.01 ± 2.27 mg QE/g DW), while trypsin hydrolysate showed greater hemolysis inhibition (259.36 ± 5.78 mg DSE/g DW) than undigested PBPs (25.25 ± 5.8 mg DSE/g DW). Together, these results underscore the potential of enzymatically derived BAPs from G. tenuistipitata PBPs as natural antioxidants and anti‐inflammatory agents, with promising applications in functional food and nutraceutical development.

31 March 2026 in Toxicant Research
Verified
Journal Article
Open access
PDF file
Tanvir Zaman ShoyshobTanvir Zaman Shoyshob
Tanvir Zaman Shoyshob
Md Jamal UddinMd Jamal Uddin
Md Jamal Uddin
Md Abdul HannanMd Abdul Hannan
Md Abdul Hannan
Toxicant exposure has emerged as a global health threat. Toxicant-induced diseases are associated with oxidative stress, inflammation, mitochondrial dysfunction, metabolic dysregulation, and regulated cell death pathways. Toxicants disrupt cellular homeostasis by activating interconnected signaling networks instead of targeting isolated molecular pathways like NF-κB, MAPKs, JAK/STAT, NRF2, HIF-1α, and p53. Recent studies also reveal emerging mechanisms, including ferroptosis, pyroptosis, necroptosis, cGAS-STING signaling, TRPM2-mediated Ca²⁺ dysregulation, ER stress, and SIRT1-dependent pathways that are central to toxicant-induced organ injury. These pathways contribute to various conditions such as neurotoxicity, chronic kidney disease, hepatotoxicity, cardiovascular complications, pulmonary fibrosis, immunotoxicity, and cancer. Additionally, systems biology and network toxicology approaches integrated with omics technologies are facilitating the mapping of dynamic toxicity networks and the identification of novel therapeutic targets. Overall, this review highlights the emerging signaling mechanisms involved in toxicant-related diseases and their potential for biomarker discovery and targeted therapies.

2 April 2026 in Immuno
Verified
Journal Article
Open access
PDF file
Tanvir Zaman ShoyshobTanvir Zaman Shoyshob
Tanvir Zaman Shoyshob
NANusrat Afrin
Nusrat Afrin
MIMd Minhajul Islam
Md Minhajul Islam
MFMithila Farjana
Mithila Farjana
MRMd. Tarek Ahmed Roni
Md. Tarek Ahmed Roni
Md Jamal UddinMd Jamal Uddin
Md Jamal Uddin
Kidney disease is an alarming universal health concern and a leading cause of morbidity and mortality. About 861 million individuals around the world suffer from kidney complications. However, current treatment alternatives are limited. These limitations underscore the urgent need for new therapeutic approaches. Autophagy is a dynamic and cellular housekeeping mechanism. The use of conditional autophagy-related gene knockouts in kidney cells has led to a better understanding of autophagy’s significance. Basal autophagy in the kidney serves as a quality control mechanism, vital for cellular metabolism and organelle homeostasis. Under stressful conditions, kidney cells adapt their autophagic activity. This process is intricately controlled by signaling pathways that control autophagic flux, with sirtuins, AMP-activated protein kinase (AMPK), and mammalian target of rapamycin (mTOR) acting as key regulators. Additionally, autophagy plays a role in the natural aging process of renal tissue. Small-molecule natural products have demonstrated efficacy in regulating autophagy and mitigating kidney damage in several experimental studies. However, specific mechanisms by which small molecules regulate autophagy across different renal disorders have yet to be fully understood. This study shows that the recent advancements in using small molecules in autophagy research have reignited interest in the related signaling pathways and their role in the pathophysiology of renal diseases. Further research on autophagy and its regulatory signaling networks could provide new therapeutic targets for small-molecule intervention in renal disorders.